These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 10083519

  • 1. Mycophenolate mofetil/Neoral/steroid vs Neoral/steroid therapy for prophylaxis of acute rejection in renal transplant recipients.
    Carmellini M, Vistoli F, Bellini R, Boggi U, Rindi P, Rizzo G, Mosca F.
    Transplant Proc; 1999; 31(1-2):1162-4. PubMed ID: 10083519
    [No Abstract] [Full Text] [Related]

  • 2. Mycophenolate mofetil (Cellcept) in renal transplantation: the European experience. The European Mycophenolate Mofetil Co-operative Study Group.
    Carl S, Wiesel M.
    Transplant Proc; 1997 Nov; 29(7):2932-5. PubMed ID: 9365619
    [No Abstract] [Full Text] [Related]

  • 3. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y, Tojimbara T, Iwadoh K, Koyama I, Nanmoku K, Kai K, Sannomiya A, Nakajima I, Fuchinoue S, Teraoka S.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):1984-92. PubMed ID: 17161352
    [Abstract] [Full Text] [Related]

  • 4. Mycophenolate mofetil in living donor renal allograft recipients.
    Park K, Moon JI, Kim SI, Kim YS.
    Transplant Proc; 1999 Dec 20; 31(1-2):1133. PubMed ID: 10083506
    [No Abstract] [Full Text] [Related]

  • 5. Prospective study of mycophenolate mofetil for the prevention of acute rejection in living donor renal allograft recipients.
    Park K, Kim SI, Moon JI, Kim YS, Kim MS.
    Transplant Proc; 1998 Nov 20; 30(7):3575. PubMed ID: 9838565
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Long-term experience with mycofenolate mofetil in the prevention of renal allograft rejection.
    Behrend M, Lueck R, Pichlmayr R.
    Transplant Proc; 1997 Nov 20; 29(7):2927-9. PubMed ID: 9365617
    [No Abstract] [Full Text] [Related]

  • 9. Mycofenolate mofetil-cyclosporine immunosuppression of kidney transplantation recipients with two different corticosteroid doses.
    Remport A, Sasvári I, Toronyi E, Borka P, Lázár N, Járay J, Perner F.
    Transplant Proc; 2001 May 20; 33(3):2302-3. PubMed ID: 11377537
    [No Abstract] [Full Text] [Related]

  • 10. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection.
    Vanrenterghem Y, Lebranchu Y, Hené R, Oppenheimer F, Ekberg H.
    Transplantation; 2000 Nov 15; 70(9):1352-9. PubMed ID: 11087152
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: results after four years.
    Höcker B, John U, Plank C, Wühl E, Weber LT, Misselwitz J, Rascher W, Mehls O, Tönshoff B.
    Transplantation; 2004 Jul 27; 78(2):228-34. PubMed ID: 15280683
    [Abstract] [Full Text] [Related]

  • 13. A prospective randomised study of CSA monotherapy versus CSA plus mycophenolate mofetil in cadaveric renal transplant recipients.
    Sells RA, Bakran A, Brown MW, Grinyo J, Hammad A, Hyatt D, Owens G.
    Transplant Proc; 1998 Dec 27; 30(8):4098. PubMed ID: 9865311
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Mycophenolate mofetil, ATG, and cyclosporine in the induction treatment of renal transplant recipients minimizes the incidence of acute rejection episodes.
    Puig JM, Lloveras J, Fernández-Crespo P, Mir M, Marcas LI, Manresa JM, Masramón J.
    Transplant Proc; 1998 Aug 27; 30(5):2226-7. PubMed ID: 9723449
    [No Abstract] [Full Text] [Related]

  • 16. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sollinger HW.
    Transplantation; 1995 Aug 15; 60(3):225-32. PubMed ID: 7645033
    [Abstract] [Full Text] [Related]

  • 17. Tacrolimus and mycophenolate mofetil in renal transplant recipients: one year results of a multicenter, randomized dose ranging trial. FK506/MMF Dose-Ranging Kidney Transplant Study Group.
    Miller J.
    Transplant Proc; 1999 Aug 15; 31(1-2):276-7. PubMed ID: 10083106
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation.
    Bruce DS, Woodle ES, Newell KA, Millis JM, Cronin DC, Loss GE, Grewal HP, Siegel CT, Pellar S, Josephson MA, Thistlethwaite JR.
    Transplant Proc; 1998 Jun 15; 30(4):1538-40. PubMed ID: 9636625
    [No Abstract] [Full Text] [Related]

  • 20. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Transplantation; 2001 Apr 27; 71(8):1091-7. PubMed ID: 11374408
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.